Sokratis Papageorgiou

Associate Professor of Neurology and Neuropsychology

National and Kapodistrian University of Athens

Greece

Research Interests

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Sokratis Papageorgiou is an Associate Professor of Neurology and Neuropsychology at the National and Kapodistrian University of Athens, Greece. His research focuses on neurodegenerative diseases, cognitive disorders, and the application of advanced imaging and artificial intelligence in diagnostics. Recent publications explore the therapeutic potential of monoclonal antibodies and the impact of cerebrospinal fluid dynamics on Alzheimer's disease, among other significant topics in neuropsychology.

Articles (29)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (16)

Nikolaos Scarmeas

Columbia University

UNITED STATES

Sokratis Papageorgiou

Research Interests

Contact this professor

About

Articles (29)

In search of the optimal MRI marker for progressive supranuclear palsy: a large, single-center, retrospective study on the effect of phenotype, diagnostic certainty and disease duration

Cognitive Decline in Parkinsonism: From Clinical Phenotypes to the Genetic Background

Can Progressive Supranuclear Palsy Be Accurately Identified via MRI with the Use of Visual Rating Scales and Signs?

Monoclonal Antibodies as Therapeutic Agents in Autoimmune and Neurodegenerative Diseases of the Central Nervous System: Current Evidence on Molecular Mechanisms and Future Directions

Cerebrospinal Fluid Erythrocyte Burden Amplifies the Impact of PTAU on Entorhinal Degeneration in Alzheimer’s Disease

AI-Based Classification of Mild Cognitive Impairment and Cognitively Normal Patients

A Narrative Review of Theranostics in Neuro-Oncology: Advancing Brain Tumor Diagnosis and Treatment Through Nuclear Medicine and Artificial Intelligence

Development of a Specialized Telemedicine Protocol for Cognitive Disorders: The TeleCogNition Project in Greece

Prospective Neuropsychological and Plasma Biomarker Changes in Treatment-Naïve People Living with HIV After Antiretroviral Treatment Initiation

The Greek Version of the Mild Behavioral Impairment Checklist (MBI-C): Psychometric Properties in Mild Cognitive Impairment Due to Alzheimer’s Disease

Precision Dopaminergic Treatment in a Cohort of Parkinson’s Disease Patients Carrying Autosomal Recessive Gene Variants: Clinical Cohort Data and a Mini Review

Unraveling the Potential Underlying Mechanisms of Mild Behavioral Impairment: Focusing on Amyloid and Tau Pathology

Emerging Therapeutic Potential of Fluoxetine on Cognitive Decline in Alzheimer’s Disease: Systematic Review

Neurological Examination via Telemedicine: An Updated Review Focusing on Movement Disorders

Multimodal Approach to Neurocognitive Function in People Living with HIV in the cART Era: A Comprehensive Review

Parkinson's Disease and Driving Fitness: A Systematic Review of the Existing Guidelines

Exploring the Genetic Landscape of Mild Behavioral Impairment as an Early Marker of Cognitive Decline: An Updated Review Focusing on Alzheimer’s Disease

Mild Behavioral Impairment in Parkinson’s Disease: An Updated Review on the Clinical, Genetic, Neuroanatomical, and Pathophysiological Aspects

The Effects of a Single Session of a Rhythmic Movement Program on Selected Biopsychological Parameters in PD Patients: A Methodological Approach

Pharmacological and Non-Pharmacological Treatments for Depression in Parkinson’s Disease: An Updated Review

Double Trouble: Association of Malignant Melanoma with Sporadic and Genetic Forms of Parkinson’s Disease and Asymptomatic Carriers of Related Genes: A Brief Report

Genetic Insights into the Molecular Pathophysiology of Depression in Parkinson’s Disease

Imaging Markers for Normal Pressure Hydrocephalus: An Overview

The nonverbal BriefScreen: A cognitive screening method for patients with limited language and motor abilities

Exploring the Role of ACE2 as a Connecting Link between COVID-19 and Parkinson’s Disease

How Well Did the Healthcare System Respond to the Healthcare Needs of Older People with and without Dementia during the COVID-19 Pandemic? The Perception of Healthcare Providers and Older People from the SI4CARE Project in the ADRION Region

Application of the AT(N) and Other CSF Classification Systems in Behavioral Variant Frontotemporal Dementia

Perceptions of Patients, Caregivers, and Healthcare Professionals toward Telemedicine Use for Cognitive and Movement Disorders in the Aegean Islands, Greece: A Pilot Study of the SI4CARE European Project

Prosopagnosia, Other Specific Cognitive Deficits, and Behavioral Symptoms: Comparison between Right Temporal and Behavioral Variant of Frontotemporal Dementia

Collaborators (16)

Nikolaos Scarmeas

Charalampos Moschopoulos

Anastasia Bougea

Ioanna Pachi

Leonidas Stefanis

PANAGIOTIS TSAKLIS

Panagiotis Bamidis

Yiannis Koutedakis

Giannis Giakas

Efthalia Angelopoulou

Vasilios C. Constantinides

A Antoniadou

Christos Koros

Katarina Vukojević

George P. Paraskevas

Christina Piperi

Make your next move.